Table 2.

Serum cholesterol concentration (mmol/L) at baseline and after two 3-week periods of coffee abstention (week 0 – 3 and week 7 – 10) for APOE ε2-positive (n = 13) and APOE ε2-negative (n = 108) individuals

	APOE ε2-positive	APOE ε2-negative	p
	n = 13	n = 107/103 a
First trial period
week 0	4.68 (0.80)	5.28 (0.93)	0.01b
week 3	4.49 (0.71)	5.05 (0.90)
diff week 0–3	-0.18 (0.24)	-0.23 (0.55)	0.30 c
p (diff 0–3)	0.02 d	<0.0001d
Second trial period
week 7	4.52 (0.71)	5.34 (0.93)
week 10	4.34 (0.64)	4.95 (0.89)
week 7–10	-0.18 (0.41)	-0.39 (0.55)	0.08 c
p (diff 7–10)	0.13	<0.0001d

^a 107 participants in the first trial period and 103 participants in the second trial period

^b Significant difference between APOE ε2-positive and APOE ε2-negative at baseline, Wilcoxon rank sum test

^c No significant difference between APOE ε2-positive and APOE ε2-negative in differences between week 0–3 or week 7–10, Wilcoxon rank sum test

^d Significant difference between week 0–3 for the APOE ε2-positive group and between week 0–3 and week 7–10 for the APOE ε2-negative group, Signed rank test